All In Biotech

Drug Trial Radar · NCT05588609

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

13

Actual

Start

Nov 17, 2022

Primary completion

Jul 3, 2025

Study completion Jul 3, 2025

Sponsor

Lead sponsor
Partner Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC

Conditions

  • NSCLC Harboring NRG1 Fusion
  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • Afatinib Oral TabletDrug

    anti epidermal growth factor receptor (EGFR)/HER2 agent

  • Enzalutamide PillDrug

    second-generation androgen receptor antagonist

  • Abiraterone acetate tabletsDrug

    androgen synthesis inhibitor

  • MCLA-128Biological

    full length IgG1 bispecific antibody targeting HER2 and HER3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Group A: Evaluate efficacy of zenocutuzumab in combination with afatinib in terms of response.Time frame: Every 8 weeks until study ends, approximately 2 years
  2. Group B: Evaluate efficacy of zenocutuzumab in combination with enzalutamide or abiraterone acetate in terms of Prostate-Specific antigen level ≥ 50% (PSA50) response.Time frame: Every 4 weeks until study ends, approximately 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope & Innovation

    Whittier, California

  • Florida Cancer Specialists

    Lake Mary, Florida

  • The Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • TriHealth Cancer Institute

    Cincinnati, Ohio

  • University Hospitals - Seidman Cancer Center

    Cleveland, Ohio

  • Northwest Medical Specialties

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.